VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

Summary

Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.

Timeline

Start

2005-03-29

Primary completion

2006-01-10

Completion

2006-01-10

Outcome

Met primary endpoint

registry MEAN VALTREX 1 g Once Daily: 1.5 (Standard Deviation 5.3) Percentage of days NCT00116844 ↗

registry VALTREX 1 g Once Daily vs Placebo; p <0.001; Nonparametric tests-Wilcoxon Rank Sum NCT00116844 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Valaciclovir	Unknown	1 g	—

Indications